Author  
Place of duty  
Title   ÁøÇàµÈ À§Àå°ü¾Ï¿¡¼­ Àú¿ë·®ÀÇ °æ±¸¿ë Leucovorin °ú 5-Fluorouracil ÀÇ Ç×¾Ï È¿°ú ( The Efficacy of 5-Fluorouracil and Low Dose Oral Leucovorin in Advanced GI Malignancies )
Publicationinfo   1990 Jan; 022(02): 329-334.
Key_word  
Full-Text  
Abstract   Eighteen patients with GI malignancies (9 gastric, 3 colorectal, 3 pancreatic and 3 hepatobiliary cancer) were treated with oral leucovorin 15 mg administered every 6 hrs and IV 5-fluorouracil (5-FU) 500 mg/m started 1 hr after oral leucovorin for 5 consecutive days. The cycle was repeated every 3 weeks. When grade III or IV toxicities appeared, dose of 5-FU was reduced to 80% of initial one. Eight of 18 patients had previous experience of 5-FU containing chemotherapy. The results of study showed no objective responder of 16 evaluable patients. Eleven of 16 (69%) had stable disease and 5 (31%) Progressed initially. The overall survival of the study group was 9-65+ weeks (median: 36 wks). Survival of patients with stable disease and those with initial progression were 9+-65+ weeks (median: 41 weeks) and 9-21 (median: 13) weeks retrospectively (p<0.05). Toxicities were mild and tolerable. The most common and dose limiting toxicity was mucositis (83.3%). We concluded low dose oral leucovorin and 5-FU was tolerable, but not effective in GI malignancies.
Àú ÀÚ   ¹®ÇѸ²(Han Lim Moon),±èÈƱ³(Hoon Kyo Kim),ÀÌ°æ½Ä(Kyung Shik Lee),Á¤Áø¿ì(Jin Woo Jung),ÀÌâµ·(Chang Don Lee),±èºÎ¼º(Boo Sung Kim),±èµ¿Áý(Dong Jip Kim),ÃÖ±ÔÈ£(Kyu Ho Choi),ÃÖ°æ¾÷(Keung Eup Choi)